Walden University

ScholarWorks
Walden Dissertations and Doctoral Studies

Walden Dissertations and Doctoral Studies
Collection

2020

Pertussis Resurgence in Europe: Incidence and Epidemiologic
Cycles in Immunization Required and Non-Required Countries
Sheryl Ann Duquet
Walden University

Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Medicine and Health Sciences Commons, and the Microbiology Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies
Collection at ScholarWorks. It has been accepted for inclusion in Walden Dissertations and Doctoral Studies by an
authorized administrator of ScholarWorks. For more information, please contact ScholarWorks@waldenu.edu.

Walden University
College of Health Sciences

This is to certify that the doctoral study by

Sheryl Ann Duquet

has been found to be complete and satisfactory in all respects,
and that any and all revisions required by
the review committee have been made.

Review Committee
Dr. Vibha Kumar, Committee Chairperson, Public Health Faculty
Dr. Richard Palmer, Committee Member, Public Health Faculty
Dr. Michael Furukawa, University Reviewer, Public Health Faculty

Chief Academic Officer and Provost
Sue Subocz, Ph.D.

Walden University
2019

Abstract

Pertussis Resurgence in Europe: Incidence and Epidemiologic Cycles in
Immunization Required and Non-Required Countries
by
Sheryl Ann Duquet

MS, Wayne State University 1997
BS, University of Michigan 1993

Doctoral Study Submitted in Partial Fulfillment
Of the Requirements for the Degree of
Doctor of Public Health

Walden University
2019

Abstract
Although pertussis vaccines have been available for over 7 decades, countries are
experiencing a pertussis resurgence. This study sought to establish a relationship
between the European pertussis immunization schedule designs (with and
without the inclusion of adolescent boosters) and the immunization requirement
(recommended or required), which potentially influences immunity waning, and
thus the incidence rate and epidemiologic cycles of pertussis. The theoretical
foundation for this study was the theory of herd immunity. A quantitative
research method was used, supported by a secondary data source. The statistical
analysis included the use of linear regression to evaluate the relationship between
the requirement of the vaccine and the addition of adolescent boosters on the
incidence level and the length of the epidemiologic cycles. The study findings
suggest that pertussis immunization, whether recommended or required, does
have an influence on the incidence rate within the populations of the countries
analyzed. The same influence on incidence was demonstrated in relation to
adolescent boosters as part of the immunization schedule. A similar relationship
was not observed between the immunization schedule requirement and design on
the epidemiologic cycles. This study provided relevant data that contributes to
the enhanced understanding of the relationship between the design of the
immunization schedule on incidence. This understanding could help control the
resurgence, reduce immune waning through adolescent boosters, enhance
immunization schedule timing, and lower the incidence. The result would be a
positive public health social change through improved immunization strategy.
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Section 1: Foundation of the Study and Literature Review
Introduction
Pertussis is the result of a human-acquired infection by the bacterium
Bordetella pertussis and to a much lesser extent Bordetella parapertussis,
transmitted via airborne droplets generated from a cough or a sneeze (Bouchez &
Guiso, 2015). B. pertussis colonizes in the respiratory tract and the toxins
contribute to the pathogenesis of the disease (Carbonetti, 2016). Pertussis has a
3-week incubation period prior to the first of three phases of the disease:
catarrhal, paroxysmal, and convalescent phase, each lasting 1–2 weeks (Locht,
2016). The catarrhal stage involves nondescript symptoms such as a sore throat,
dry cough, runny nose, and in less than 20% of infected individuals, a fever. The
spasmodic stage is characterized by a paroxysmal cough, episodes of cyanosis
from coughing and vomiting. The convalescent stage is the final stage of the
disease, which brings a reduction in the severity of the cough and other related
symptoms (Calvert & Heath, 2017). There are also several secondary
complications associated with pertussis, which can prove fatal in infants, such as
pneumonia, apnea, leukocytosis, and pulmonary hypertension (Carbonetti,
2016).
In the early 1900s, before the development of pertussis vaccines, it was
understood that pertussis was not just a disease affecting children but a disease
that was also found in adults, albeit in a much milder and less acute form (Clark,
2014). Following the development and use of whole-cell pertussis vaccines, the
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incidence of the disease was significantly reduced. However, it was understood
that the pertussis vaccines did not provide lifelong immunity (Clark, 2014).
Pertussis generally occurs in episodic cycles of 3–5 years, providing evidence that
although the incidence of pertussis can be reduced, the transmission of the
disease can continue throughout the population (Clark, 2014).
The purpose of vaccination for diseases like pertussis is to reduce the
severity and mortality associated with the disease (World Health Organization
[WHO], 2016). The causative agent of pertussis, B. pertussis, was determined in
1906. The bacterium, B. pertussis, was utilized to create the first vaccine against
pertussis. The vaccine created was a whole-cell vaccine (Saadatian-Elahi et al.,
2016). In 1940, clinical trial data became available, which supported the
effectiveness of the whole-cell vaccine against pertussis (Clark, 2014). Pertussis
whole-cell vaccines have been recommended for use in developed countries since
the 1940s. This vaccine was eventually used globally until the 1990s when an
acellular vaccine was developed with a safer safety profile. The acellular vaccine
was adopted in many of the developed countries around the globe. However,
most developing countries continue to utilize the whole-cell pertussis vaccine for
economic reasons (Esposito & Principi, 2016). It is estimated that approximately
70% of the countries around the globe still utilize whole-cell pertussis vaccines
(Bouchez & Guiso, 2015).
After the transition in some developed countries to the acellular pertussis
vaccines, it was discovered that the immune response to the vaccine was not as
long lasting as the pertussis whole-cell vaccine (Guiso et al., 2017). Although
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acellular pertussis vaccines do not produce the undesired side effects that the
pertussis whole-cell vaccines do, they are not as effective in sustaining immunity
as the whole-cell vaccines (Guiso et al., 2017). The lack of immune efficacy is
likely due to the difference in how immunity is established in the body (Guiso et
al., 2017). The pertussis acellular vaccine induces an immune response, which
involves T helper 2 response without the involvement of T memory cells. The
pertussis whole-cell vaccine activates T helper 1 and 17 response with the
involvement of B and T memory cells. The immunologic pathway of the wholecell vaccine provides longer lasting immunity (Guiso et al., 2017).
Because pertussis was long viewed as a disease of only infants and
preadolescent children, immunization schedule recommendations for both
acellular and whole-cell vaccines were structured to administer the primary series
in Year 1 of life, followed by two boosters in Year 2 and Year 3/4 (Esposito &
Principi, 2016). While whole-cell vaccines were in use, boosters were not
administered to adolescents and adults because the side effects of the vaccine
were more severe in older individuals. The introduction of acellular vaccines
allowed for the introduction of boosters beyond the primary vaccination series
provided in infants and young children (Bouchez & Guiso, 2015).
The structure of the immunization schedules provided a significant
reduction in pertussis until a gradual increase of pertussis incidence was
observed in the 1980s in areas with high pertussis vaccination rates (Esposito &
Principi, 2016). Additionally, the incidence of pertussis diagnosed in adolescents
and adults was increasing. In an attempt to reduce the pertussis incidence,
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recommendations for adolescent and adult boosters were also added to the
immunization schedules in many countries (Esposito & Principi, 2016).
Pertussis is a disease that remains prevalent globally despite the fact that
vaccines have been available since the 1940s (Locht, 2016). In some developed
areas of the globe, where the pertussis vaccines have been in use for decades,
such as the United States, United Kingdom, and Australia, a resurgence of
pertussis has occurred (Sealy, Belcher, & Preston, 2016). Multiple significant
outbreaks have occurred. These outbreaks have yielded different epidemiology
compared to prior years. The main epidemiological difference is the age of the
individuals contracting pertussis. Since the 1990s, while still considerably high in
infants, the adolescent incidence of pertussis has been increasing (Sealy, Belcher,
& Preston, 2016).
The resurgence of pertussis is a phenomenon that is occurring in both
developed and developing countries throughout the world (Chen & He, 2017).
The resurgence has estimated rates of infection for developed countries by up to
12% and up to 50% in developing countries. The incidence rate for this vaccinepreventable disease is most significant in children under the age of 2, with fatality
rates of 0.2% in developed countries and 4% in developing countries (Chen & He,
2017). Both developed and developing countries have observed an
epidemiological shift in an increase of pertussis in adolescents and adults (Chen
& He, 2017).
Adolescents and adults are believed to be the primary source of infection
transmission to children under the age of 2 years. Recognition of the
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epidemiological shift in an increase of pertussis in adolescents and adults is
significant. because adolescents and adults have been found to be the primary
source of infection of unprotected infants (Terranella et al., 2016). This is
because of the epidemiological shift in the increase of pertussis in adolescents
and adults, and the immune waning associated with the implementation of
acellular pertussis vaccines, the understanding of the potential of the relationship
between the design and requirement of pertussis immunization schedules on
pertussis incidence and the associated epidemiologic cycles could assist in
controlling the pertussis resurgence, reducing immune waning, enhancing
immunization schedules, and lowering the incidence of pertussis, thus resulting
in positive public health social change through improved immunization strategy.
Problem Statement
Despite the availability of pertussis vaccines for over 70 years, countries
are experiencing a resurgence of pertussis among their populations (Della-Torre,
Benevides, Pereira de Melo, & Ferreira, 2015). Globally, the annual estimate of
the incidence of pertussis is up to 40 million cases; these are associated with
approximately 300,000 deaths (Muloiwa, Kagina, Engel, & Hussy, 2015). The
actual worldwide incidence of pertussis has not been accurately determined
because of the variability in the reporting and collection of the epidemiology. The
variability in the collection of the data has a significant effect on the
understanding of the true incidence of pertussis (Esposito & Principi, 2016).
Another significant aspect associated with pertussis that has not been
determined is a complete understanding of the disease pathogenesis.
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Additionally, although the pertussis vaccines, both acellular and whole-cell, have
been effective in reducing the incidence of pertussis, the immunological
mechanisms of B. pertussis are not well understood (Lapidot & Gill, 2016). The
use of the acellular pertussis vaccine has been linked to the resurgence of
pertussis in developed countries due to evidence of immune waning. In addition
to immune waning, there has also been an upsurge in the number of
asymptomatic infections in adolescents, thus leading to increased transmission of
the disease (Sealy, Belcher, & Preston, 2016). Pertussis is pervasive throughout
the world; the true magnitude of its pervasiveness is unknown and is complicated
due to the fact that asymptomatic pertussis infection is common in adolescents
and adults (Sealy, Belcher, & Preston, 2016).
Older children, adolescents, and adults can also develop the disease, but
the illness is not as severe as it is in infants, pregnant women, and the elderly,
who are at higher risk for contracting pertussis (Guiso, 2014). An age incidence
trend has also emerged as part of the resurgence of pertussis. The incidence
involving adolescents in the age range of 13–16 has surfaced as a change in the
historical trending of the disease. Infants, mainly those less than 3 months old,
have the highest rate of pertussis-related deaths (Centers for Disease Control and
Prevention [CDC], 2017). The increase in the incidence of detected and
undetected pertussis in the adolescent and adult populations, along with immune
waning, is believed to play a significant role in the continuation of the reservoir of
circulating pertussis, and thus in the resurgence of pertussis in countries with
well-established vaccination rates (Esposito & Principi, 2016).
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A review of the literature on pertussis resurgence reveals gaps in
understanding the cause and contributing factors associated with the resurgence.
The literature does suggest some potential causes for the resurgence of pertussis,
such as changes in the vaccine, bacterial genetic variations in the bacterium,
immunity waning, and pertussis vaccine effectiveness (Althouse & Scarpino,
2015). Two additional proposed causes for the pertussis resurgence are the
timing of initial and booster vaccination schedules (Riolo & Rohani, 2015) and
the asymptomatic transmission of the disease caused by inadequate booster
immunization coverage (Althouse & Scarpino, 2015).
The use of vaccines is an essential tool to protect public health against
pertussis. Not only do vaccines protect the immunized individual, but they also
create a state of herd immunity that protects the population (Sabbe &
Vandermeulen, 2016). Pertussis vaccines have played a protective role in
reducing the incidence of pertussis. However, with the implementation of
acellular vaccines, immunity is waning at a more rapid rate than with whole-cell
vaccines (Sabbe & Vandermeulen, 2016). There is also a significant variation in
pertussis primary vaccination schedules globally. The type of vaccine utilized for
the primary series, including the mixing of vaccine types during the series, also
varies globally (WHO, 2016). A gap identified in the literature, and the focus of
this study, is the understanding of the potential relationship between the type of
acellular pertussis vaccine in use and the pertussis vaccination schedule, whether
recommended or mandatory, has as contributing factors to the country’s
pertussis incidence and epidemiologic cycles. Additionally, the impact that a
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country’s requirement for pertussis immunization, whether recommended or
required, is also a gap in the literature.
Data collected via surveillance and statistical modeling provide evidence
that the continued use of acellular pertussis vaccines will lead to an increased
pertussis resurgence. The resurgence increases because, as immunity wanes
following immunization, the risk of fatality to the unimmunized children who
may contract the disease increases (WHO, 2016). The extent, severity, and timing
of the resurgence are not known. The factors that play a potential role in the
resurgence of pertussis, such as vaccine type, the structure of the vaccine
schedule, and the vaccine coverage, need to be evaluated to lower the incidence of
pertussis and stop the resurgence of the disease (WHO, 2016).
Purpose of the Study
This doctoral study was to establish if there was any relationship between
the pertussis immunization schedule design (with and without the inclusion of
adolescent boosters) and the immunization requirement (recommended or
required), which potentially influences immunity waning, and thus the incidence
rate and epidemiologic cycles of pertussis within a country’s population. Multiple
European countries with recommended and mandatory pertussis immunization
schedules were included in the study. Immunity waning is suggested to be a
contributing factor in the increase in pertussis incidence in both economically
developed and developing countries (Sealy, Belcher, & Preston, 2016). This study
provided evidence of the potential relationships associated with immunization
schedule design and the immunization requirement on the incidence and
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frequency of epidemiologic cycles. The study findings related to immunization
schedule design and the immunization requirement could also be utilized by
health professionals to address the health and medical needs of populations that
are at an elevated risk of contracting pertussis.
Research Questions and Hypotheses
This study was guided by the following four e research questions:
1. RQ1: Is there any association between the pertussis vaccine schedule
that is required by the European country and the incidence level of
pertussis? The null hypothesis (H0) is that there is not an association
between the pertussis vaccine schedule that is required by the
European country and the incidence level of pertussis. The alternative
hypothesis (H1) is that there is an association between the pertussis
vaccine schedule that is required by the European country and the
incidence level of pertussis.
2. RQ2: Is there any association between the pertussis vaccine schedule
that is required by the European country and the epidemiologic cycles
of pertussis? The null hypothesis (H0) is that there is not an
association between the pertussis vaccine schedule that is required by
the European country and the epidemiologic cycles of pertussis. The
alternative hypothesis (H1) is that there is an association between the
pertussis vaccine schedule that is required by the European country
and the epidemiologic cycles of pertussis.
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3. RQ3: Is there any association between the European country’s addition
of required adolescent boosters to the pertussis vaccine schedule and
incidence level of pertussis? The null hypothesis (H0) is that there is
not an association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and the
incidence level of pertussis. The alternative hypothesis (H1) is that
there is an association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and the
incidence level of pertussis.
4. RQ4: Is there any association between the European country’s addition
of required adolescent boosters to the pertussis vaccine schedule and
the length of the epidemiologic cycles? The null hypothesis (H0) is that
there is not an association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and the
length of the epidemiologic cycles. The alternative hypothesis (H1) is
that there is an association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and the
length of the epidemiologic cycles.
Theoretical Foundation for the Study
The theoretical foundation for this doctoral study was the theory of herd
immunity, that is, the indirect protection received by individuals who are
susceptible to a given disease from those individuals in the population who are
immune to the same given disease (Plans-Rubio, 2014). The theory of herd
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immunity suggests that infectious diseases that are contracted person-to-person
are limited when a critical proportion of the population or the herd immunity
threshold is protected through vaccination or natural immunity to the infectious
disease, thus reducing the potential prevalence or resurgence of the disease in the
population (Plans-Rubio, 2014). The reduction in the incidence of infectious
disease is termed the herd effect (Holland & Chase, 2014). If herd immunity in a
population does not meet the required threshold, the herd effect will still provide
a protective buffer of the population against the infectious disease (Holland &
Chase, 2014).
The pertussis vaccine aids in protecting individuals who are immunized
from contracting pertussis (Domenech de Cellès, Riolo, Magpantay, Rohani, &
King, 2014). However, research related to the transmission effects of pertussis is
lacking and needs to be better defined. The incidence rates in populations that
have high pertussis vaccination rates suggest that there is a herd immunity effect
(Domenech de Cellès et al., 2014). Additionally, in populations with high
pertussis vaccination rates, there is data to suggest that reduced transmission,
shorter epidemiologic cycles, and reduction in the incidence of pertussis in
unvaccinated infants strengthens the existence of herd immunity in the
population (Domenech de Cellès et al., 2014).
The primary objective of pertussis immunization programs is the
reduction of disease and the associated mortality, and the potential
establishment of population herd immunity (Nitsch-Osuch et al., 2013).
Vaccination schedules for pertussis vary significantly among the countries of the
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world (Nitsch-Osuch et al., 2013). Adherence to vaccination schedules and the
use of appropriately timed boosters, when immunity against pertussis waning is
suspected, are essential to the establishment of herd immunity (Nitsch-Osuch et
al., 2013). Data from research studies have provided evidence that European
countries need to incorporate booster vaccinations into their immunization
schedules to strengthen individual and population protection, and the
establishment of strong herd immunity against pertussis infection and
transmission (Nitsch-Osuch et al., 2013). This study utilized four research
questions to understand if there was any relationship between the pertussis
immunization schedule design and the immunization requirement, which
potentially influences immunity waning, and thus the incidence rate and
epidemiologic cycles of pertussis within a country’s population. The dependent
and independent variables linked with the research questions also helped
establish if the vaccination schedule design, immunization requirement, and use
of booster vaccinations provided evidence of a population herd immunity effect
based on pertussis incidence.
Nature of the Study
This study utilized a quantitative research method, supported by a
secondary data source, to help address the research questions. The quantitative
research approach was used to evaluate the potential relationship between the
requirement of the pertussis vaccine (recommended or required), and the
addition of recommended or required adolescent boosters, on the incidence level
and the length of the epidemiologic cycles of pertussis. The quantitative approach
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used aspects of descriptive analysis, measures of central tendency, and
correlation coefficients for the statistical analysis. Additionally, the statistical
analysis included measures of dispersion and inferential statistics.
The dependent variable for RQ1 was the pertussis incidence within the
country’s population. The independent variable for RQ1 was the pertussis vaccine
schedule required by the country. The dependent variable for RQ2 was the
pertussis epidemiologic cycles of pertussis within the country’s population. The
independent variable for RQ2 was the pertussis vaccine schedule required by the
country. The dependent variable for RQ3 was the pertussis incidence level of
pertussis within the country’s population. The independent variable for RQ3 was
the country’s addition of required adolescent boosters to the pertussis vaccine
schedule recommended by the country. The dependent variable for RQ4 was the
length of the epidemiologic cycles of pertussis within the country’s population.
The independent variable for RQ4 was the country’s addition of recommended
adolescent boosters to the pertussis vaccine schedule required by the country.
Literature Review Search Strategy
The literature review was carried out with the following databases:
PubMed, Science Direct, CINAHL, Medline, and Google Scholar. The following
search terms were used: pertussis, vaccines, resurgence, schedules, boosters,
asymptomatic, incidence, and epidemiologic cycles. The review was limited to a
5-year timeframe, and focused on information gathered from peer-reviewed
journals.
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Literature Review and Related Key Variables and/or Concepts
Pertussis is a vaccine-preventable disease, but the incidence of the disease
continues to rebound in countries with high vaccination rates (Esposito &
Principi, 2016). The expert panel assembled for the 2015 Pertussis: Biology,
Epidemiology, and Prevention Conference determined that improving current
vaccine strategies, as well as the creation of more effective vaccines would be
required to address the ongoing challenges with the global control of pertussis.
The panel of experts determined that there are multiple factors associated with
the continued elevated incidence, and in some countries, the resurgence of
pertussis despite adequate vaccination programs. The factors identified were
vaccine strategy, population composition, surveillance systems, and methods of
detection (Saadatian-Elahi et al., 2016).
Tan et al. (2015) examined the pertussis incidence trends from a global
aspect and determined that underreporting of pertussis is a significant problem.
Under-reporting of pertussis is most prevalent in adult and adolescent
populations. Global under-reporting of pertussis appears to be in part associated
with several factors, such as the type of surveillance system, the robustness of the
surveillance system, health system infrastructure, and healthcare technological
capabilities (Tan et al., 2015). The adolescent and adult populations are the most
challenging to detect pertussis incidence due to the generalized characteristics
and the lessened severity of pertussis in the adolescent and adult populations. In
the adolescent and adult populations, pertussis presents as a persistent, but not
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severe cough, unlike the severe illness experienced by young children and infants
(Tan et al., 2015).
European countries have experienced a resurgence of pertussis, as the
other regions around the globe have, despite having established immunization
programs and surveillance systems in place (Heiniger et al., 2016). Due to the
multifaceted aspects of the disease dynamics associated with pertussis, the cause
of the resurgence of pertussis in Europe and other regions of the world has not
been established. However, it has been determined that the transmission of
pertussis by adolescents and adults with waning pertussis immunity has caused
the continuation of pertussis epidemiologic cycles in European countries
(Heiniger et al., 2016).
There are two important aspects of the available pertussis vaccines, which
is protection from disease and infection (Locht, 2016). Recommendations based
on current research suggest that countries who have not yet switched to the
acellular vaccine do not make the switch to aid in better protection against
infection and to increase disease control. It has also been recommended that until
more effective pertussis vaccines are developed, the optimal use of current
vaccines is needed to control infection and prevent disease (Locht, 2016).
Gambhir et al. (2015) utilized epidemiological modeling to examine the
recent pertussis upsurge in the United States. The modeling identified variations
in the pertussis efficacy and immune protection duration. The study compared
whole-cell and acellular vaccines. The study results indicated the need to perform
more extensive modeling to examine alternative pertussis vaccination schedules,
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to aid in addressing the resurgence. The alternate vaccination schedules would
include adjustments to the age of vaccination, the age of booster doses, and
cocooning strategies (Gambhir, Clark, Cauchemez, Tartof, Swerdlow, & Ferguson,
2015).
Choi, Campbell, Amirthalingam, Jan van Hoek, and Miller (2016)
developed a mathematical model to examine the transmission of pertussis to gain
an understanding of the revival of pertussis in the countries of England and
Wales. The model also examined the potential effect of the introduction of the
addition of a different vaccination schedule. The modeling presented data that
indicated that countries currently using a pertussis whole-cell vaccine should not
transition to an acellular vaccine unless enhanced vaccination strategies are
developed. Additionally, the modeling indicated that a more effective pertussis
vaccine is needed to lessen the resurgence (Choi, Campbell, Amirthalingam, Jan
van Hoek, & Miller, 2016).
Believing that the change from a whole-cell to an acellular vaccine has
influenced the pertussis resurgence in the country of New Zealand, Radke,
Petousis-Harris, Watson, Gentles, and Turner (2016) examined the effectiveness
of the acellular vaccine schedule utilized in New Zealand. The authors found that
the vaccine protection from the immunization schedule only provides protection
through age four. The study concluded that introducing a pertussis vaccine
booster at age six would enhance childhood immunity (Radke, Petousis-Harris,
Watson, Gentles, & Turner, 2016).
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Definitions
Adolescent Booster: Supplemental doses of a vaccine intended to boost the
immunity of an adolescent (U.S. Health and Human Services, 2018).
Asymptomatic Infection: Infection occurring with apparent symptoms
(U.S. Health and Human Services, 2018).
Epidemiologic Cycle: The length of time between the increase of pertussis
incidence over time in a given population (Domenech de Celles, Magpantay,
King, & Rohani, 2016).
Herd Immunity: The indirect protection received by individuals who are
susceptible to a given disease from those individuals in the population who have
immunity to the same given disease (Plans-Rubio, 2014).
Immunization Schedule: Is a schedule of immunization requirements
based on age, number of doses, and timing of the doses of a vaccine (Kim, D,
Bridges, & Harriman, 2015).
Pertussis Incidence: The quantity of new pertussis cases reported
associated with a population during a defined period (U.S. Health and Human
Services, 2018).
Pertussis Resurgence: The increase in the incidence of reported pertussis
cases (Kilgore, Salin, Zervos, & Schmitt, 2016).
Pertussis Acellular Vaccine: A vaccine made from purified components of
inactivated bacteria Bordetella pertussis (Kilgore, Salin, Zervos, & Schmitt,
2016).
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Pertussis Whole-Cell Vaccine: A vaccine made from a suspension of whole
inactivated Bordetella pertussis bacteria (Kilgore, Salin, Zervos, & Schmitt,
2016).
Recommended Immunization: Vaccines that are recommended, but not
required by law for specific populations as part of the national immunization
program of a given country (Haverkate et al., 2012).
Required Immunization: Vaccines that are required by law for specific
populations as part of the national immunization program of a given country
(Haverkate et al., 2012).
Waning Immunity: The reduction or loss of immune protecting antibodies
over a period of time (U.S. Health and Human Services, 2018).
Assumptions
The data associated with the data set utilized for this study were presumed
to be accurate. The database contained data from 1980 to 2017 and was updated
annually. The database utilized for the study was the most up-to-date available.
Scope and Delimitations
The WHO database, Vaccine-Preventable Disease: Monitoring System
2018 Global Summary (WVPDMSGS), contains global vaccination data.
European countries utilizing acellular pertussis vaccines with recommended and
required immunization schedules were chosen for the study. Understanding any
identified differences in pertussis incidence and epidemiologic cycles potentially
associated with immunization schedules helped develop an awareness of the
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potential need for the adjustment of immunization schedule strategies to
strengthen waning immunity.
Social Significance
This study was expected to provide data to help explain the factors that
may be contributing to the resurgence and persistence of pertussis; the data
generated from this doctoral study was expected to provide an enhanced
understanding of the relationship between the design and requirement of the
immunization schedule on pertussis incidence and epidemiologic cycles.
Understanding the potential of this relationship could assist in controlling the
pertussis resurgence, reduce immune waning, enhance immunization schedules,
and lower the incidence of pertussis resulting in positive social change through
improved immunization strategy. Specifically, the study outcomes could be
applied in the field of public health through improvements in immunization
schedules and strategies to be used in vaccination programs, and then
appropriately applied within economically developed and developing countries.
Summary
Pertussis vaccines have been available for more than 70 years, but
countries around the globe are experiencing a resurgence of pertussis among
their populations (Della-Torre, Benevides, Pereira de Melo, & Ferreira, 2015).
The global annual estimate of the incidence of pertussis is more than 40 million
cases; these are associated with approximately 300,000 deaths (Muloiwa, Kagina,
Engel, & Hussy, 2015). The true worldwide incidence of global pertussis has not
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been determined because of the significant variability in the reporting and
collection of epidemiologic data (Esposito & Principi, 2016).
Following the development and use of whole-cell pertussis vaccines, the
incidence of pertussis was significantly reduced. However, it was understood that
these vaccines did not provide lifelong immunity (Clark, 2014). Pertussis
generally occurs in cycles of 3 to 5 years, providing evidence that although the
incidence of pertussis can be reduced, the transmission of the disease can
continue throughout the population (Clark, 2014).
A gap identified in the literature was the understanding of the potential
relationship between the type (acellular or whole-cell) of pertussis vaccine in use,
and whether the pertussis vaccination schedule has contributing factors to the
country’s pertussis incidence and epidemiologic cycle. An additional gap in the
literature associated with pertussis was the impact of a country’s pertussis
vaccination requirement, whether recommended or required, on the country’s
pertussis incidence and epidemiologic cycles. Therefore, the aim of this study was
to establish whether there is any relationship between the pertussis
immunization schedule design (with and without the inclusion of adolescent
boosters) and the immunization requirement (recommended or required), which
could influence immunity waning, and thus the incidence rate and epidemiologic
cycles of pertussis within the country’s population.
Multiple European countries with recommended and mandatory pertussis
immunization schedules were included in the study. The study used a
quantitative research method, supported by a secondary data source, to help
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address the research questions. A quantitative research approach was used to
evaluate the potential relationship between the requirement of the pertussis
vaccine (recommended or required) and the addition of recommended or
required adolescent boosters on the incidence level and the length of the
epidemiologic cycles of pertussis. This doctoral study provided data to help
explain the factors that may be contributing to the resurgence and persistence of
pertussis. Additionally, the data generated from this doctoral study provided an
enhanced understanding of the relationship between the design and requirement
of the immunization schedule on pertussis incidence and epidemiologic cycles.
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Section 2: Research Design and Data Collection
Introduction
The purpose of this section is to describe and outline the research design
and method of data collection. The research design examines the potential
association between the pertussis immunization schedule design (with and
without the inclusion of adolescent boosters) and the immunization requirement
(recommended or required). The association of the vaccine schedule and
immunization requirement potentially influence immunity waning, and thus the
incidence rate and epidemiologic cycles of pertussis within the country’s
population. Multiple European countries with recommended and mandatory
pertussis immunization schedules are included in the study.
Research Design and Rationale
The secondary data source that was utilized in this study was the
WVPDMSGS. The selected database was developed by the WHO. The database
offers global pertussis data associated with population data, reported cases,
vaccination rates, immunization schedules, and immunization indicators (WHO,
2017). The data associated with the recommendation or requirement of pertussis
immunization schedules was collected from the European Centre for Disease
Prevention and Control Vaccine Scheduler (European Centre for Disease
Prevention and Control, 2018).
The WVPDMSGS was selected because it provides the population
information required to answer the research questions at the country level. The
European countries chosen to be assessed in the doctoral study were based on
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their requirement for pertussis immunization vaccine used within the country
and the inclusion of adolescent boosters in the vaccine schedule. All of the
European countries chosen used acellular pertussis vaccines.
The WVPDMSGS database was used to examine this study’s four research
questions. Each of the four research questions involved the examination of the
required (mandatory by law) immunization schedule or the recommended
(voluntary) immunization schedule of the European countries involved in the
study. The dependent variable for RQ1 was the pertussis incidence within the
country’s population. The independent variable for RQ1 was the pertussis vaccine
schedule required by the country. The dependent variable for RQ2 was the
pertussis epidemiologic cycles of pertussis within the country’s population. The
independent variable for RQ2 was the pertussis vaccine schedule required by the
country. The dependent variable for RQ3 was the pertussis incidence level of
pertussis within the country’s population. The independent variable for RQ3 was
the country’s addition of required adolescent boosters to the pertussis vaccine
schedule recommended by the country. The dependent variable for RQ4 was the
length of the epidemiologic cycles of pertussis within the country’s population.
The independent variable for RQ4 was the country’s addition of recommended
adolescent boosters to the pertussis vaccine schedule required by the country.
Methodology
Population
The population consisted of European countries utilizing pertussis
acellular vaccines. The countries were selected based on their recommendations
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or required pertussis immunization schedules. Additionally, countries
recommending and requiring adolescent pertussis vaccines were included.
Sampling Procedure
Secondary data from the WVPDMSGS database was used for this doctoral
study. The WVPDMSGS database contains immunization data that is assembled
and assessed on an annual basis. The WHO works in partnership with the United
Nations Children’s Fund (UNICEF) to collect the data that populates the
WVPDMSGS database (WHO, 2011).
The primary source of the data for the database is collected using joint
reporting forms that were created in collaboration with WHO, UNICEF, and the
ministries of health from participating member states. The forms were created to
collect information associated with the participating countries' immunization
coverage, reported vaccine-preventable diseases, immunization schedules, and
immunization system performance indicators (WHO, 2011). Additional data
included in the database is collected from the published literature that is
evaluated by WHO, UNICEF, and experts from the locations referenced in the
literature, UNICEF historical databases, and surveys provided by participating
ministries of health (WHO, 2011).
The data were sampled based on the date range and countries selected to
be evaluated as part of the doctoral study. A power analysis was performed to
determine the sample size required to assure statistical significance. The data was
not be altered from the reported values. IRB approval through Walden University
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to utilize the secondary data was obtained prior to evaluating the data (12-24-180543758).
Instrumentation and Operationalization of Constructs
This doctoral study used secondary data from a public database. The
database used was the WVPDMSGS database. The database data was collected
and verified by WHO, UNICEF, and select ministries of health and is updated on
a yearly basis. The process of establishing the validity and reliability of the data
used to populate the database was performed by WHO, UNICEF, local experts,
and external reviewers.
The WVPDMSGS database was established in 2010 following a
retrospective review by WHO and UNICEF of immunization data starting in the
year 2000. The data being evaluated extended back to 1980 (WHO, 2011). The
2010 database was created to establish an accurate estimate of the immunization
coverage of a variety of vaccine-preventable diseases (Burton et al., 2009). Since
2010, the database has been updated on an annual basis (WHO, 2011). WHO
and UNICEF collaborate with the individual countries, working closely with them
to understand and improve the accuracy and quality of the data (Burton et al.,
2009).
The data collected for the database came from four primary sources,
official immunization data reported from WHO member states, UNICEF historic
immunization database, published literature, and surveys from ministries of
health (WHO, 2011). The data were evaluated for a true reflection of
immunization performance and potentially compromised data, as well as for
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potential biases, factualness of the information, and to verify that the data was
obtained from reliable sources (WHO, 2011). The method used to evaluate and
compile the data involves eight principles, which are: using evidence-based data,
country-specific data, consistent patterns and trends, local expertise, no
averaging of data, no smoothing of data, no 100% coverage of data, and
determining the proportion of live births utilizing a mathematical model (WHO,
2011).
The process of data evaluation was conducted in multiple steps. The data
is first collected and then was reviewed by WHO and UNICEF to check for
accuracy against the reported national data, assessing if the data is compromised
or inaccurate in regards to immunization coverage (WHO, 2011). Discrepancies
are handled by contacting the reporting country to investigate discrepancies.
Whenever possible, WHO and UNICEF work with experts from the reporting
countries. Based on the official data reviewed and evaluated, draft estimates of
immunization coverage are calculated (WHO, 2011).
The next step in the data evaluation process was to have the data reviewed
by national authorities. The national authorities review the data for accuracy
based on local knowledge and expertise. Following the national authority review,
the draft estimates are revised by the WHO and UNICEF (WHO, 2011). The last
step in the data evaluation process was to have the data undergo an external
review by immunization experts with specialized expertise in immunization
systems and methodology associated with surveys. Any additional revisions, as an
outcome of the external review, are performed by WHO and UNICEF, and the
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data was then added to the database and disseminated for public access (WHO,
2011).
The operationalization of the variables collected for the doctoral study is
outlined in Table 1. The variable data was obtained from the WVPDMSGS
database. The nominal variables are immunization schedule recommended,
immunization schedule required, adolescent boosters recommended, and
adolescent boosters required. The categorical variables are pertussis incidence
and length of the epidemiologic cycle.

Table 1
Operationalization of Variables Collected from WHO Vaccine-Preventable
Disease: Monitoring System 2018 Global Summary database
_______________________________________________________
Variable
Values
Research Question
_______________________________________________________
Pertussis incidence
Value
RQ 1, 3
Immunization schedule required

Yes/No

RQ 1, 2

Length of epidemiologic cycle

Value

RQ 2, 4

Adolescent boosters required

Yes/No

RQ 3, 4

_______________________________________________________

Data Analysis Plan
The intention of the doctoral study was to establish if there was any
relationship between the pertussis immunization schedule design (with versus
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without the inclusion of adolescent boosters) and the immunization requirement
(recommended versus required), which potentially influences immunity waning,
and thus the incidence rate and epidemiologic cycles of pertussis within the
country’s population. Data from this study were analyzed using SPSS version 24.
SPSS version 24 was used to screen and clean the data before the data is used in
the analysis of the research questions. The data were assessed for any missing
variables, outliers, skewness, and to assure that the variables meet the statistical
assumptions that are associated with the statistical analysis that will be
performed as part of the doctoral study.
The data analyzed from the WVPDMSGS database focused on European
countries utilizing acellular pertussis vaccines. The quantitative research
approach was used to evaluate the potential relationship between the
requirement of the pertussis vaccine (recommended versus required) and the
addition of recommended versus required adolescent boosters on the incidence
level and the length of the epidemiologic cycles of pertussis. The quantitative
approach used aspects of descriptive analysis, measures of central tendency, and
correlation coefficients for the statistical analysis. The qualitative approach also
included a determination of the P-value, confidence intervals, mean, standard
deviation, and F-test as specific tests of statistical significance. Additionally, the
statistical analysis included linear regression to evaluate the potential
relationship between the requirement of the pertussis vaccine (recommended
versus required) and the addition of recommended versus required adolescent
boosters on the incidence level and the length of the epidemiologic cycles of

29

pertussis for each of the respective research questions that have been broken out
into four independent questions.
In order to understand the relationship amid the dependent variable and
the independent variable associated with the research question, linear regression
analysis was used to evaluate the research question. The linear regression
analysis aided in predicting the value of the dependent variable based on the
independent variable in order to understand the nature of the relationship
between the variables. The linear regression analysis also assisted in
understanding how dependent variable changes in conjunction with changes in
the independent variable associated with the research question. The results of the
linear regression analysis were interpreted by examining the correlation and
direction of the research data, evaluating the best fitting line, and assessing the
strength of the relationship between the variables. Specifically, the data analysis
will involve determining and assessing the linear regression equation, the
coefficient of the multiple determination (R2), the significance level, and the
confidence intervals. This statistical approach was applied to all four research
questions.
Due to undiscernible differences in the outcome of the linear regression as
it relates to the independent variables from the research questions analyzed via
linear regression, ANOVA was utilized to determine if there is a significant
difference between the independent variables. The ANOVA allowed for a
potential determination of the variance between the variables by comparing the
means of the independent variables. Specifically, the descriptive statistics, such
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as the mean, standard deviation, standard error, and confidence intervals were
evaluated. Additionally, the Sum of Squares, Mean Square, and significance levels
were determined to aid in the analysis. This additional statistical approach was
applied to all four research questions.
RQ1: Is there any association between the pertussis vaccine schedule that
is required by the European country and the incidence level of pertussis? The
null hypothesis (H0) is that there is not an association between the pertussis
vaccine schedule that is required by the European country and the incidence level
of pertussis. The alternative hypothesis (H1) is that there is an association
between the pertussis vaccine schedule that is required by the European country
and the incidence level of pertussis. The dependent variable for RQ1 is the
pertussis incidence (number of reported cases) within the country’s population.
The independent variable for RQ1 is the pertussis vaccine schedule required by
the country (Yes/No). The research question was analyzed with linear regression
to determine a potential relationship between the independent and dependent
variables. The statistical analysis included a determination of the P-value,
confidence intervals, mean, standard deviation, and F-test as specific tests of
statistical significance. ANOVA was applied to determine if there was a difference
between the independent variables from the research questions analyzed via
Linear regression.
RQ2: Is there any association between the pertussis vaccine schedule that
is required by the European country and the epidemiologic cycles of pertussis?
The null hypothesis (H0) is that there is not an association between the pertussis
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vaccine schedule that is required by the European country and the epidemiologic
cycles of pertussis. The alternative hypothesis (H1) is that there is an association
between the pertussis vaccine schedule that is required by the European country
and the epidemiologic cycles of pertussis. The dependent variable for RQ2 is the
pertussis epidemiologic cycles (length of time between spikes in incidence) of
pertussis within the country’s population. The independent variable for RQ2 is
the pertussis vaccine schedule required by the country (Yes/No). The research
question was analyzed with linear regression to determine a potential
relationship between the independent and dependent variables. The statistical
analysis included a determination of the P-value, confidence intervals, mean,
standard deviation, and F-test as specific tests of statistical significance. ANOVA
was applied to determine if there was a difference between the independent
variables from the research questions analyzed via Linear regression.
RQ3-Quantitative: Is there any association between the European
country’s addition of required adolescent boosters to the pertussis vaccine
schedule and incidence level of pertussis. The null hypothesis (H0) is that there is
not an association between the European country’s addition of required
adolescent boosters to the pertussis vaccine schedule and the incidence level of
pertussis. The alternative hypothesis (H1) is that there is an association between
the European country’s addition of required adolescent boosters to the pertussis
vaccine schedule and the incidence level of pertussis. The dependent variable for
RQ3 is the pertussis incidence level of pertussis (number of reported cases)
within the country’s population. The independent variable for RQ3 is the
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country’s addition of required adolescent boosters to the pertussis vaccine
schedule recommended by the country (Yes/No). The research question was
analyzed with linear regression to determine a potential relationship between the
independent and dependent variables. The statistical analysis included a
determination of the P-value, confidence intervals, mean, standard deviation, and
F-test as specific tests of statistical significance. ANOVA was applied to
determine if there was a difference between the independent variables from the
research questions analyzed via Linear regression.
RQ4: Is there any association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and the length of
the epidemiologic cycles. The null hypothesis (H0) is that there is not an
association between the European country’s addition of required adolescent
boosters to the pertussis vaccine schedule and the length of the epidemiologic
cycles. The alternative hypothesis (H1) is that there is an association between the
European country’s addition of required adolescent boosters to the pertussis
vaccine schedule and the length of the epidemiologic cycles. The dependent
variable for RQ4 is the length of the epidemiologic cycles (length of time between
spikes in incidence) of pertussis within the country’s population. The
independent variable for RQ4 is the country’s addition of recommended
adolescent boosters to the pertussis vaccine schedule required by the country
(Yes/No). The research question was analyzed with linear regression to
determine a potential relationship between the independent and dependent
variables. The statistical analysis included a determination of the P-value,
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confidence intervals, mean, standard deviation, and F-test as specific tests of
statistical significance. ANOVA was applied to determine if there was a difference
between the independent variables research questions analyzed via linear
regression.
Threats to Validity
This doctoral study has potential threats to the internal and external
validity of the data being used to assess the research questions. Some of the
potential internal validity threats are associated with the data contained in the
WVPDMSGS database. Although the data was evaluated for accuracy and
reliability, the entry of the data into the database and the aggregation of the data
from the various reporting sources can be a potential threat to validity if they are
not performed per the WHO and UNICEF prescribed principles. Additionally, the
validity of the data could also be compromised if adequate reviews of the data are
not performed by the WHO, UNICEF, local experts, and external reviewers.
External validity threats also exist associated with the WVPDMSGS
database. External threats to the validity of the data being used to assess the
research questions are the accuracy of the reporting and calculation of the
immunization coverage from the participating member states. Additionally,
biases can be created if the participating member states fail to report portions of
the population, or over or underestimate the vaccination coverage and incidence
of the vaccine-preventable diseases.
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Ethical Procedures
Walden University IRB approval was obtained to use the public
WVPDMSGS secondary data for this doctoral study. The data contained in the
WVPDMSGS does not include any data that is required to be de-identified. The
data was handled in an ethical manner during the statistical evaluation. All of
Walden University's ethical procedures were followed during the statistical
analysis of the doctoral study data. Following the statistical analysis of the data in
SPSS, and completion of the doctoral study, the data will be protectively stored in
the SPSS format, along with a copy of the WVPDMSGS database for the
prescribed period under Walden University policy.
Summary
The research design utilized in this doctoral study examined the potential
association between the pertussis immunization schedule design (with and
without the inclusion of adolescent boosters) and the immunization requirement
(recommended or required). The secondary data source that was used in the
doctoral research study was the WVPDMSGS.
The study population consisted of European countries utilizing pertussis
acellular vaccines. The countries were selected based on their recommendations
or required pertussis immunization schedules. Additionally, countries
recommending and requiring adolescent pertussis vaccines were included. The
study hypotheses were evaluated via SPSS version 24 software. The four research
questions explored were (a) is there any association between the pertussis
vaccine schedule that is required by the European country and the incidence level
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of pertussis, (b) is there any association between the pertussis vaccine schedule
that is required by the European country and the epidemiologic cycles of
pertussis, (c) is there any association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and incidence level
of pertussis, and (d) is there any association between the European country’s
addition of required adolescent boosters to the pertussis vaccine schedule and the
length of the epidemiologic cycles.
A quantitative research approach was used to evaluate the potential
relationship between the requirement of the pertussis vaccine (recommended or
required) and the addition of recommended or required adolescent boosters on
the incidence level and the length of the epidemiologic cycles of pertussis. The
quantitative approach used aspects of descriptive analysis, measures of central
tendency, and correlation coefficients for the statistical analysis. Additionally, the
statistical analysis included measures of dispersion and inferential statistics.
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Section 3: Presentation of Results and Findings
Introduction
The aim of this doctoral study was to establish whether there was any
relationship between the pertussis immunization schedule design (with and
without the inclusion of adolescent boosters) and the immunization requirement
(recommended or required), which potentially influences immunity waning, and
thus the incidence rate and epidemiologic cycles of pertussis within the country’s
population. The dependent variables examined in the study were the pertussis
incidence within a country’s population and the pertussis epidemiologic cycles of
pertussis within a country’s population. The independent variables examined
were the pertussis vaccine schedule recommended by the country, the pertussis
vaccine schedule required by the country, the country’s addition of recommended
adolescent boosters to the pertussis vaccine schedule, and the addition of
required adolescent boosters to the pertussis vaccine schedule required by the
country. The research questions and associated hypotheses are presented below.
1. RQ1: Is there any association between the pertussis vaccine schedule that
is required by the European country and the incidence level of pertussis?
H01: There is not an association between the pertussis vaccine schedule
that is required by the European country and the incidence level of
pertussis. H11: There is an association between the pertussis vaccine
schedule that is required by the European country and the incidence level
of pertussis.
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2. RQ2: Is there any association between the pertussis vaccine schedule that
is required by the European country and the epidemiologic cycles of
pertussis?
H02: There is not an association between the pertussis vaccine schedule
that is required by the European country and the epidemiologic cycles of
pertussis.
H12: There is an association between the pertussis vaccine schedule that is
required by the European country and the epidemiologic cycles of
pertussis.
3. RQ3: Is there any association between the European country’s addition of
H03: There is not an association between the European country’s addition
of required adolescent boosters to the pertussis vaccine schedule and the
incidence level of pertussis.
H13: There is an association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and the
incidence level of pertussis.
4. RQ4: Is there any association between the European country’s addition of
H04: There is not an association between the European country’s addition
of required adolescent boosters to the pertussis vaccine schedule and the
length of the epidemiologic cycles.
H14: There is an association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and the
length of the epidemiologic cycles.
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This section outlines the presentation of the results and findings of the
doctoral study. In addition to the introduction, which describes the aim of the
doctoral study, research questions, and the associated hypotheses, the section
provides a description of the data collection, and the secondary data set used to
answer the doctoral study research questions. Additionally, the results obtained
from the linear regression analysis are described and discussed for each of the
research questions. Lastly, the data analysis findings and interpretations are
summarized.
Data Collection of Secondary Dataset
Secondary data from the WVPDMSGS database was used to explore the
research questions associated with this doctoral study. The WVPDMSGS
database contains immunization data that is assembled and assessed on an
annual basis. The WHO works in partnership with UNICEF to collect the data
that populates the WHO Vaccine-Preventable Disease: Monitoring System Global
Summary database (WHO, 2011).
The primary source of the data for the database is collected using joint
reporting forms that were created in collaboration with WHO, UNICEF, and the
ministries of health from participating member states. The forms were created to
collect information associated with the participating country's immunization
coverage, reported vaccine-preventable diseases, immunization schedules, and
immunization system performance indicators (WHO, 2011). Additional data
included in the database is collected from the published literature that is
evaluated by WHO, UNICEF, and experts from the locations referenced in the

39

literature, UNICEF historical databases, and surveys provided by participating
ministries of health (WHO, 2011). The database data is collected and verified by
WHO, UNICEF, and select ministries of health and is updated on a yearly basis.
The process of establishing validity and reliability of the data used to populate the
database is performed by WHO, UNICEF, local experts, and external reviewers.
The first stage in the evaluation of the secondary data from the
WVPDMSGS database was to identify which European Union countries require
pertussis immunization schedule, and which European Union countries have
recommended pertussis immunization schedules. Additionally, which European
Union countries required, or recommended adolescent pertussis booster needed
to be determined. The European Centre for Disease Prevention and Control
Vaccine Scheduler was utilized to determine the recommendation or requirement
of pertussis immunization schedules and adolescent boosters. There was a total
of 29 European Union countries identified that had a required or recommended
pertussis immunization schedule. Nine of the European Union countries required
pertussis immunization schedules and 20 had recommended pertussis
immunization schedules.
The secondary data from the WVPDMSGS database was reviewed based
on the identified European Union countries. The date range evaluated as part of
the doctoral study was from 2010 to 2017, in order to stay within the last decade.
The criteria set for missing data per country was no more than one data point
could be missing. The criteria set for the population range was greater than one
million people, but less than 11 million people. The countries that meet the
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established criteria were Austria, Bulgaria, Croatia, Czech Republic, Denmark,
Estonia, Hungary, Ireland, Latvia, Lithuania, Norway, Portugal, Slovakia,
Slovenia, and Sweden. Of the 15 countries that meet the missing data and
population criteria, 7 had required pertussis immunization schedules, and 8 had
recommended pertussis immunization schedules. The incidence data for each of
the 15 selected European Union countries were normalized by dividing the
incidence per 100,000 people.
The data for the epidemiologic cycles was evaluated by taking the average
of the 8 years being evaluated for each of the 15 selected European Union
countries and then determining the value above or below the baseline incidence
per country. The data evaluation resulted in a data set containing 117 data
points. The adolescent pertussis booster data was also evaluated. It was
determined that of the seven countries that required pertussis immunization
schedules, five of the seven required adolescent pertussis boosters. In regard to
the eight European Union countries that recommended pertussis immunization
schedules, six of the eight countries also had recommended adolescent pertussis
boosters as part of the immunization schedule. The four European Union
countries without a required or recommended adolescent European booster as
part of the pertussis immunization schedule, were Denmark, Portugal, Croatia,
and Latvia. The data evaluation resulted in a data set containing 86 data points.
Analysis
The doctoral study statistical analysis included the use of linear regression
to evaluate the potential relationship between the requirement of the pertussis
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vaccine (recommended versus required) and the addition of recommended
versus required adolescent boosters on the incidence level and the length of the
epidemiologic cycles of pertussis for each of the respective research questions
that have been broken out into four independent questions. Linear regression
required an independent variable and one dependent variable to perform the
analysis for each of the research questions.
In order to understand the potential relationship between the dependent
variable and the independent variable associated with the research question,
linear regression analysis was used to evaluate the research questions. The linear
regression analysis aided in predicting the value of the dependent variable based
on the independent variable in order to understand the nature of the relationship
between the variables. The linear regression analysis also assisted in
understanding how the dependent variable changed in conjunction with changes
in the independent variable associated with the research questions. The outcome
of the linear regression analysis was interpreted by examining the correlation and
direction of the research data, evaluating the best fitting line, and assessing the
strength of the relationship between the variables. The data analysis involved
determining and assessing the linear regression equation, the coefficient of the
multiple determination (R2), the significance level, and the confidence intervals.
This statistical approach was applied to all four research questions.
ANOVA was utilized to determine if there is a significant difference
between the independent variables associated with the research questions. The
ANOVA allowed for the potential determination of the variance between the
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variables by comparing the means of the independent variables. The descriptive
statistics, such as the mean, standard deviation, standard error, and confidence
intervals, were evaluated. Additionally, the Sum of Squares, Mean Square, and
significance levels were determined to aid in the analysis. This statistical
approach was applied to all four research questions.
Results
Research Question 1
The data associated with research question 1 was analyzed utilizing Linear
regression. The research questions was:
RQ 1: Is there any association between the pertussis vaccine
schedule that is required by the European country and the
incidence level of pertussis?
The linear combination of required and recommended immunization
schedules was found to be significantly related to pertussis incidence in the
European countries evaluated as part of the doctoral study. The R2 = .056, F
(1,115) = 6.78, p = .010. The Coefficient of Determination was .056, indicating
that approximately 5.6% of the variance in the dependent variable pertussis
incidence in the population can be accounted for by the linear relationship of the
independent variable of required and recommended immunization schedules.
The descriptive characteristics, linear regression model summary, ANOVA, and
linear regression coefficients data are exhibited in Tables 2, 3, 4, and 5 below.
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Table 2
Descriptive Characteristics of Vaccine Schedule Type and Incidence of Pertussis
_______________________________________________________
Variable
N
Mean
Std Dev
_______________________________________________________
Pertussis incidence
117
10.8651
17.49083
Required schedule

117

.4701

.50125

Recommended schedule

117

.5299

.50125

_______________________________________________________

The mean of the pertussis incidence was 10.8651. The mean of the recommended
schedule data was larger than the mean of the required schedule data by .0598.

Table 3
Linear Regression Associated with the Relationship of Vaccine Schedule Type
and Incidence of Pertussis
_______________________________________________________
Model N
R Square Adjusted R Square Standard Error of the Estimate
_______________________________________________________
117 .236
.056
.047
17.07051
_______________________________________________________

Table 4
ANOVA Associated with the Relationship of Vaccine Schedule Type and
Incidence of Pertussis
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_______________________________________________________
Model
Sum of Squares
df
Mean Squares
F
Sig
_______________________________________________________
Regression
1976.503
1
1976.503
6.783
.010
Residual

33511.264

115

Total

35487.768

116

291.402

_________________________________________

The F-Test, with a value of 6.783, indicates that the independent variables
(required or recommended schedules) do have explanatory power over the
dependent variable (pertussis incidence). The significance (P value) was .010,
which is less than .05.

Table 5
Linear Regression Coefficient Associated with the Relationship of Vaccine
Schedule Type and Incidence of Pertussis
_______________________________________________________
Model
N
Coeff Std Error t
sig 95% Conf Lower 95% Conf Upper
_______________________________________________________
Required 117
3.162
2.604 .010
1.972
14.498

The value of t falls between the lower and upper confidence limits for both the
recommended and required schedules. The t value was 2.604, with a 95% lower
confidence limit of 1.972 and a 95% upper confidence limit of 14.498. The
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coefficients had a positive relationship. The effect size was .236 indicating a small
level of relationship. The significance (P value) was .010, which is less than .05,
thus rejecting the null hypothesis.

Research Question 2
The data associated with Research Question 2 were analyzed via linear
regression. The research questions was:
RQ2: Is there any association between the pertussis vaccine schedule that
is required by the European country and the epidemiologic cycles of
pertussis?
The linear combination of required and recommended immunization
schedules was not significantly related to pertussis epidemiologic cycles in the
European countries evaluated as part of the doctoral study. The R2 = .001, F
(1,115) = .119, p = .731. Coefficient of Determination was .001. Therefore, the
required or recommended immunization schedules are not a good predictor of
the pertussis epidemiologic cycles in the European countries evaluated as part of
the doctoral study. The descriptive characteristics, linear regression model
summary, ANOVA, and linear regression coefficients data are exhibited in Tables
6, 7, 8, and 9 below.

Table 6
Descriptive Characteristics of Vaccine Schedule Type and Epidemiologic Cycles
of Pertussis
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_______________________________________________________
Variable
N
Mean
Std Dev
_______________________________________________________
Pertussis cycle
117
.3335
10.33511
Required schedule

117

.4701

Recommended schedule

117

.5299

.50125
.50125

_______________________________________________________

The mean of the pertussis cycle was .3335. The mean of the recommended
schedule data was larger than the mean of the required schedule data by .0598.

Table 7
Linear Regression Associated with Vaccine Schedule Type and Epidemiologic
Cycles of Pertussis
_______________________________________________________
Model N R R Square Adjusted R Square Standard Error of the Estimate
_______________________________________________________
117 .032 .001
- .008
10.37460
_______________________________________________________

Table 8
ANOVA Associated with the Vaccine Schedule Type and the Epidemiologic
Cycles of Pertussis
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_______________________________________________________
Model
Sum of Squares
df
Mean Squares
F
sig
_______________________________________________________
Regression
12.771
1
12.503
.119
.731
Residual

12377.717

115

Total

12390.488

116

107.632

_______________________________________________________

The F-Test, with a value of .119, indicates that the independent variables
(required or recommended schedules) do not have explanatory power over the
dependent variable (pertussis cycle). The significance (P value) was .731, which is
greater than .05.

Table 9
Linear Regression Associated with Vaccine Schedule Type and Epidemiologic
Cycles of Pertussis
_______________________________________________________
Model
N Coeff Std Error t
sig
95% Conf Lower 95% Conf Upper
_______________________________________________________
Required 117
1.922
.344 .731
-3.145
4.468
_______________________________________________________
The value of t falls between the upper and lower confidence limits for both the
recommended and required schedules. The t-value was .344, with a 95% lower
confidence limit of -3.145 and a 95% upper confidence limit of 4.468. The
coefficients had a positive relationship. The effect size was .032 indicating a small
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relationship. The significance (P value) was .731, which is greater than .05, thus
not rejecting the null hypothesis.

Research Question 3
The data associated with Research Question 3 was analyzed utilizing
Linear regression. The research questions was:
RQ3: Is there any association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and
incidence level of pertussis?
The linear combination of the addition of a required or recommended
adolescent booster was significantly related to pertussis incidence in the
European countries evaluated as part of the doctoral study. The R2 = .063, F
(1,84) = 5.680, p = .019. The coefficient of determination was .063, indicating
that approximately 6.3% of the variance of the dependent variable pertussis
incidence in the population can be accounted for by the linear combination of the
independent variable of required and recommended adolescent boosters. The
descriptive characteristics, linear regression model summary, ANOVA, and linear
regression coefficients data are exhibited in Tables 10, 11, 12, and 13 below.

Table 10
Descriptive Characteristics Associated with Adolescent Booster Schedule Type
and Incidence of Pertussis

49

_______________________________________________________
Variable

N

Mean

Std Dev

_______________________________________________________
Pertussis incidence

86

12.4801

19.60548

Required schedule

86

.470

.502

Recommended schedule

86

.530

.502

_______________________________________________________

The mean of the pertussis incidence was 12.4801. The mean of the recommended
schedule data was larger than the mean of the required schedule data by .060.

Table 11
Linear Regression Associated with Adolescent Booster Schedule Type and
Incidence of Pertussis
_______________________________________________________
Model N

R

R Square Adjusted R Square Standard Error of the Estimate

_______________________________________________________
86

.252

.063

.052

19.08712

_______________________________________________________

Table 12
ANOVA Data Associated with Adolescent Booster Schedule Type and Incidence
of Pertussis
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_______________________________________________________
Model

Sum of Squares

df

Mean Squares

F

Sig

_______________________________________________________
Regression

2069.147

1

2069.147

Residual

30602.723

84

364.318

Total

32671.870

85

5.680

.019

The F-Test, with a value of 5.680, indicates that the independent variables
(required or recommended schedules) do have explanatory power over the
dependent variable (booster incidence). The significance (P value) was .019,
which is less than .05.

Table 13
Linear Regression Associated with Adolescent Booster Schedule Type and
Incidence of Pertussis
_______________________________________________________
Model
N Coeff Std Error t
sig 95% Conf Lower 95% Conf Upper
_______________________________________________________
Required 86

4.126

2.383

.019

1.628

18.040

_______________________________________________________
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The value of t falls between the upper and lower confidence limits for both the
recommended and required schedules. The t-value was 2.83, with a 95% lower
confidence limit of 1.628 and a 95% upper confidence limit of 18.040. The
coefficients had a positive relationship. The effect size was .252 indicating a small
relationship. The significance (P value) was .019, which is less than .05, thus
rejecting the null hypothesis.

Research Question 4
The data associated with Research Question 4 was analyzed utilizing
European Center. The research question was:
RQ 4: Is there any association between the European country’s addition of
required adolescent boosters to the pertussis vaccine schedule and the
length of the epidemiologic cycles?
The linear combination of the addition of a required or recommended
adolescent booster was not significantly related to pertussis epidemiologic cycles
in the European countries evaluated as part of the doctoral study. The R2 = .001,
F (1,84) = .120, p = .730. coefficient of determination was .001. Therefore, the
required or recommended adolescent boosters are not a good predictor of the
pertussis epidemiologic cycles in the European countries evaluated as part of the
doctoral study. The descriptive characteristics, linear regression model summary,
ANOVA, and linear regression coefficients data are exhibited in Tables 14, 15, 16,
and 17 below.
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Table 14
Descriptive Characteristics Associated with Adolescent Booster Schedule Type
and Length of Epidemiologic Cycles
_______________________________________________________
Variable
N
Mean
Std Dev
_______________________________________________________
Pertussis Booster Cycle

86

.4643

11.51829

Required schedule

86

.470

.502

Recommended schedule

86

.530

.502

_______________________________________________________

The mean of the pertussis cycle was .4643. The mean of the recommended
schedule data was larger than the mean of the required schedule data by .060.

Table 15
Linear Regression Associated with Adolescent Booster Schedule Type and
Length of Epidemiologic Cycles
_______________________________________________________
Model N

R

R Square Adjusted R Square Standard Error of the Estimate

_______________________________________________________
86

.038

.001

-.010

11.57836

_______________________________________________________
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Table 16
ANOVA Associated with Adolescent Booster Schedule Type and Length of the
Epidemiologic Cycles
_______________________________________________________
Model
Sum of Squares
df
Mean Squares
F
Sig
_______________________________________________________
Regression
16.503
1
16.121
.120
.730
Residual

11260.907

84

Total

11277.028

85

134.058

_______________________________________________________

The F-Test, with a value of .120, indicates that the independent variables
(required or recommended schedules) do not have explanatory power over the
dependent variable (pertussis booster cycle). The significance (P value) was .730,
which is greater than .05, thus not rejecting the null hypothesis.

Table 17
Linear Regression Associated with Adolescent Booster Schedule Type and
Length of Epidemiologic Cycles
_______________________________________________________
Model
N Coeff Std Error t
sig
95% Conf Lower 95% Conf Upper
_______________________________________________________
Required 86
2.503
.347 .730
-4.110
5.846
_______________________________________________________
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The value of t falls between the upper and lower confidence limits for both the
recommended and required schedules. The t-value was .347, with a 95% lower
confidence limit of -4.110 and a 95% upper confidence limit of 5.846. The
coefficients had a positive relationship. The effect size was .038 indicating a small
relationship. The significance (P value) was .730, which is greater than .05, thus
accepting the null hypothesis.
Summary
The study findings from Research Question 1 suggests that the pertussis
immunization, whether recommended or required, does have an influence on the
incidence rate of pertussis within the populations of European countries analyzed
as part of this doctoral study. The same influence on pertussis incidence was
demonstrated within the populations of European countries analyzed as part of
this doctoral study related to the recommended or required adolescent boosters
that were part of the pertussis immunization schedule. This influence was
demonstrated through Research Question 3.
The doctoral study data also revealed via Research Question 2 that the
pertussis immunization, recommended or required, does not have a relationship
with the epidemiologic cycle of pertussis within the populations of European
countries analyzed as part of the doctoral study. The same lack of relationship on
the epidemiologic cycle of pertussis was demonstrated via Research Question 4
within the populations of European countries analyzed as part of this doctoral
study related to recommended or required adolescent boosters as part of the
pertussis immunization schedule.
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The next section of this doctoral study examines the interpretation of the
results of the Four research questions. Additionally, an overview of the study
limitations, recommendations for future research, implications for professional
practice, and social change are presented. Lastly, Section 4 provides a conclusion
of the findings of this doctoral study.
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Section 4: Application of Professional Practice and Implications for Social
Change
Introduction
The purpose of this doctoral study was to establish if there is any
relationship between the pertussis immunization schedule design (with and
without the inclusion of adolescent boosters) and the immunization requirement
(recommended or required), which potentially influences immunity waning and
thus the incidence rate and epidemiologic cycles of pertussis within a country’s
population. Multiple European countries with recommended and mandatory
pertussis immunization schedules were included in this study. The findings
suggest that there is evidence of potential relationships associated between the
immunization schedule and the immunization requirement on the incidence of
pertussis. The same relationship was not observed between the epidemiologic
cycles, the inclusion of adolescent boosters, and the incidence of pertussis.
Interpretation of Findings
The findings of this study via Research Questions 1 and 3 supported two of
the research studies discussed in the section, Literature Review Related to Key
Variables and/or Concepts, which mathematically modeled the effectiveness of
acellular immunization strategies. Gambhir et al. (2015) utilized epidemiological
modeling to examine the recent pertussis upsurge in the United States. The
modeling identified variations in pertussis efficacy and immune protection
duration of acellular vaccines. The results of the modeling pointed to the
potential immune waning of acellular vaccines, and the fact that booster doses

57

added to the immunization schedules may help reduce epidemics, thus lowering
pertussis incidence (Gambhir, Clark, Cauchemez, Tartof, Swerdlow, & Ferguson,
2015).
The other mathematical modeling study was performed by Choi,
Campbell, Amirthalingam, Jan van Hoek, and Miller (2016), who developed a
mathematical model to examine the transmission of pertussis to understand the
revival of pertussis in the countries of England and Wales. The results of the
mathematical modeling indicated that the protection of the acellular vaccines did
not appear as effective as the original whole-cell vaccine, thus creating an
immune waning. The modeling predicted that if an adolescent booster were
added to the immunization schedule, the pertussis incidence in infants could be
lowered (Choi, Campbell, Amirthalingam, Jan van Hoek, & Miller, 2016).
The study evaluated the incidence and epidemiologic cycles of 15
European countries in relation to the required or recommended immunization
schedule and required or recommended inclusion of an adolescent booster. The
countries that met the established criteria were Austria, Bulgaria, Croatia, Czech
Republic, Denmark, Estonia, Hungary, Ireland, Latvia, Lithuania, Norway,
Portugal, Slovakia, Slovenia, and Sweden. The outcome of the linear regression
analysis was interpreted by determining and assessing the linear regression
equation, the coefficient of the multiple determination (R2), the significance level,
and the confidence intervals.
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Research Question 1
The data associated with Research Question 1 were analyzed utilizing
linear regression. The outcome of the linear regression analysis revealed that the
null hypothesis, which was that no association between the pertussis vaccine
schedule that is required or recommended by the European country and the
incidence level of pertussis be rejected. The alternative hypothesis—that there
was an association between the pertussis vaccine schedule that is required or
recommended by the European country and the incidence level of pertussis—was
supported by the results. Although there was not a strong linear relationship
between the required or recommended immunization schedules and the
incidence of pertussis, data analysis found that there was a significant
relationship between the independent variable and the dependent variable.
The linear combination of required and recommended immunization
schedules was found to be significantly related to pertussis incidence in the
European countries evaluated as part of the doctoral study. The Coefficient of
Determination was .056, indicating that approximately 5.6% of the variance in
the dependent variable pertussis incidence in the population can be accounted for
by the linear relationship of the independent variable of required and
recommended immunization schedules. This relationship supports the work of
Gambhir et al. (2015), whose study results indicated the need to perform more
extensive modeling to examine alternative pertussis vaccination schedules, to aid
in addressing the resurgence. This doctoral study confirmed a relationship
between the schedule type and the incidence of pertussis, which also supported
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the Locht (2016) study results. Locht (2016) recommended that until more
effective pertussis vaccines are developed, the optimal use of current vaccines is
needed to control infection and prevent disease.
The theory of herd immunity suggests that infectious diseases that are
contracted person to person are limited when a critical proportion of the
population or the herd immunity threshold is protected through vaccination or
natural immunity to the infectious disease, thus reducing the potential
prevalence or resurgence of the disease in the population (Plans-Rubio, 2014).
Although there was not a strong linear relationship between the required or
recommended immunization schedules and the incidence of pertussis, the fact
that there was a significant relationship between the independent variables of
required or recommended immunization schedules and the dependent variable of
the incidence of pertussis supports the theory of herd immunity by verifying the
relationship between vaccination and incidence.
Research Question 2
The data associated with Research Question 2 were analyzed utilizing
Linear regression. The outcome of the linear regression analysis revealed that the
null hypothesis had no association between the pertussis vaccine schedule that is
required or recommended by the European country and the epidemiologic cycles
of pertussis, for Research Question 2 was supported by the results. The
alternative hypothesis that there is an association between the pertussis vaccine
schedule that is required or recommended by the European country and the
epidemiologic cycles of pertussis was not supported by the results and was
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rejected. The data analysis found that there was not a significant relationship
between the independent variable and the dependent variable.
The linear combination of required and recommended immunization
schedules was not significantly related to pertussis epidemiologic cycles in the
European countries evaluated as part of the doctoral study. The coefficient of
determination was .001. Therefore, the required or recommended immunization
schedules are not a good predictor of the pertussis epidemiologic cycles in the
European countries evaluated as part of the doctoral study.
Although the required or recommended immunization schedules are not a
good predictor of the pertussis epidemiologic cycles, the data obtained from this
doctoral study does support findings from the research of Tan et al. (2015). Tan
et al. (2015), suggested that the adolescent and adult populations are the most
challenging to detect pertussis incidence due to the generalized characteristics
and the lessened severity of pertussis in the adolescent and adult populations.
The persistence of pertussis associated with the immune waning of the acellular
vaccine in the adolescent and adult populations could account for the lack of
relationship between the required or recommended immunization schedules and
the epidemiologic cycles identified in this doctoral study.
The lack of a relationship between the required or recommended immunization
schedules and the pertussis epidemiologic cycles could suggest a low-level
persistence of pertussis in the population caused by the immune waning of the
acellular vaccines. The lack of a relationship between the immunization schedule
types and the pertussis epidemiologic cycles would also support the theory of
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herd immunity. If herd immunity in a population does not meet the required
threshold, the herd effect will still provide a protective buffer of the population
against the infectious disease (Holland & Chase, 2014).
Research Question 3
The data associated with Research Question 3 were analyzed utilizing
linear regression. The outcome of the linear regression analysis revealed that the
null hypothesis, that there is no association between the European country’s
addition of recommended adolescent boosters to the pertussis vaccine schedule
and incidence level of pertussis, for Research Question 3 be rejected. The
alternative hypothesis, that there was an association between the European
country’s addition of recommended adolescent boosters to the pertussis vaccine
schedule and incidence level of pertussis, was supported by the results. Although
there was not a strong linear relationship between the required or recommended
immunization schedules and the incidence of pertussis, the data analysis found
that there was a significant relationship between the independent variable and
the dependent variable.
The linear combination of the addition of a required or recommended
adolescent booster was found to be significantly related to pertussis incidence in
the European countries evaluated as part of the doctoral study. The coefficient of
determination was .063, indicating that approximately 6.3% of the variance of the
dependent variable pertussis incidence in the population can be accounted for by
the linear combination of the two independent variables of required and
recommended adolescent boosters. The addition of an adolescent booster to the
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required or recommended immunization schedule has a stronger relationship to
the incidence of pertussis than did the required or recommended immunization
schedule without an adolescent booster. This finding supports the work of
Gambhir et al. (2015), which concluded that there is a need for alternate
vaccination schedules which would include adjustments to the age of vaccination,
the age of booster doses, and cocooning strategies to help address the resurgence
and persistence of pertussis. Additionally, the work of Radke et al. (2016) found
that the vaccine protection from the immunization schedule only provides
protection through age four. Further concluding that introducing a pertussis
vaccine booster would enhance childhood immunity.
The primary objective of pertussis immunization programs is the
reduction of disease and the associated mortality, and the potential
establishment of population herd immunity (Nitsch-Osuch et al., 2013). The
linear combination of the addition of a required or recommended adolescent
booster was found to be significantly related to pertussis incidence in the
European countries evaluated as part of the doctoral study. Additionally, the
inclusions of an adolescent booster to immunization schedule type has a stronger
relationship to the incidence of pertussis than did the immunization schedule
type without an adolescent booster. These findings support the work of Osuch et
al., (2013). Osuch et al., (2013) concluded in their research that the adherence to
vaccination schedules and use of appropriately timed boosters, when immunity
against pertussis waning is suspected, are essential to the establishment of herd
immunity (Nitsch-Osuch et al. 2013). Osuch et al. (2013) further concluded in
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their research that the data provided evidence that European countries need to
incorporate booster vaccinations into their immunization schedules to strengthen
individual and population protection, and the establishment of strong herd
immunity against pertussis infection and transmission (Nitsch-Osuch et al.,
2013).
Research Question 4
The data associated with Research Question 4 were analyzed utilizing
Linear regression. The outcome of the linear regression analysis revealed that the
null hypothesis that there is no association between the European country’s
addition of required adolescent boosters to the pertussis vaccine schedule and the
length of the epidemiologic cycles for Research Question 4 was supported by the
results. The alternative hypothesis that there is there any association between the
European country’s addition of required adolescent boosters to the pertussis
vaccine schedule and the length of the epidemiologic cycles, was not supported by
the results and was rejected. The data analysis found that there was not a
significant relationship between the independent variable and the dependent
variable.
Although the addition of required adolescent boosters to the pertussis
vaccine schedule and the length of the epidemiologic cycles did not show a
relationship, the data obtained from this doctoral study do support findings from
the research of Tan et al., (2015), as did the findings from Research Question 4.
Tan et al. (2015) suggested that the adolescent and adult populations are the
most challenging to detect pertussis incidence due to the generalized
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characteristics and the lessened severity of pertussis in the adolescent and adult
populations. As stated in the findings for Research Question 2, the persistence of
the pertussis associated with the immune waning of the acellular vaccine in the
adolescent and adult populations could account for the lack of relationship
between the required or recommended immunization schedules with the addition
of adolescent boosters and the epidemiologic cycles identified in this doctoral
study.
The lack of a relationship between the required or recommended
immunization schedules and the pertussis epidemiologic cycles could suggest a
low-level persistence of pertussis in the population caused by the immune waning
of the acellular vaccines. The lack of a relationship between the immunization
schedule types and the pertussis epidemiologic cycles would also support the
theory of herd immunity. If herd immunity in a population does not meet the
required threshold, the herd effect will still provide a protective buffer of the
population against the infectious disease (Holland & Chase, 2014). However, it
has been determined that the transmission of pertussis by adolescents and adults
with waning pertussis immunity has caused the continuation of pertussis
epidemiologic cycles in European countries (Heiniger et al., 2016).
Limitations of the Study
There were several limitations to the generalizability and validity of the
data associated with the doctoral study. One of the limitations was that the data
presented in the WVPDMSGS database for several of the European Union
countries had missing data associated with the timeframe of interest from 2010
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to 2017. Because several of the countries were missing a significant number of
data points, the countries were not included in the study. Therefore, the study
results were not reflective of all of the European Union countries. Additionally,
the data associated with the data set utilized for this doctoral study are presumed
to be accurate, but there are factors that could threaten the data accuracy.
Although the data is evaluated for accuracy and reliability, the entry of the data
into the database and the compilation of the data from the various reporting
sources could be a potential threat to validity, if they were not performed per the
WHO and UNICEF prescribed principles.
The validity of the data could also have been compromised if adequate
reviews of the data were not performed by the WHO, UNICEF, local experts, and
external reviewers. External validity threats also potentially exist associated with
the WVPDMSGS database. External threats to the validity of the data being used
to assess the research questions are the accuracy of the reporting and calculation
of the immunization coverage from the participating member states.
Additionally, biases could have been created if the participating member states
failed to report portions of the population, or over or underestimated the
vaccination coverage and incidence of the vaccine-preventable diseases.
Recommendations
The results of the study suggested that there is a connection between the
immunization schedule and the timing and requirement for pertussis
immunizations. Additional research is required to more thoroughly examine the
timing based on the age of the immunization schedules. Additionally, the data
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from this doctoral study suggests that adolescent booster plays a role in
contributing to the level of pertussis incidence in the European Union countries
examined in this doctoral study. The addition of adolescent boosters to all
pertussis immunization schedules, along with the timing and number of doses
should be examined to determine the role that adolescent boosters contribute to
the resurgence and persistence of pertussis.
Implications for Professional Practice and Social Change
The doctoral study results showed a relationship between immunization
schedule types that were required or recommended on the incidence of pertussis.
Furthermore, the immunization schedule types with the addition of an adolescent
booster revealed a relationship associated with pertussis incidence rates. The
data presented in this doctoral study also established a lack of a relationship with
the immunization schedule type, required or recommended, and the design of the
pertussis immunization schedule associated with epidemiologic cycles. The
outcomes from this doctoral study, along with further research into the
vaccination age and timing of the vaccinations associated with pertussis
immunization schedules, could be applied in the field of public health to make
significant improvements to pertussis immunization schedules to be used in the
pertussis vaccination programs. The stated improvements to the pertussis
immunization programs could reduce immune waning and, thus, lower the
incidence of pertussis.
The data generated from this doctoral study provides physicians and
government health agencies with an enhanced understanding of the relationship
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between the design and requirement of the immunization schedule on the
incidence of pertussis and epidemiologic cycles. The data supports the need for
the consideration of physicians and government health agencies regarding the
implementation of required standardized immunization schedules, with the
addition of an adolescent booster to the pertussis vaccination programs. The
outcomes of this doctoral study also support the need to expand the research
related to adolescent boosters and the role that they play in immune waning
associated with acellular pertussis vaccines, along with the contribution that the
immune waning has on the resurgence of pertussis.
This doctoral study assisted in providing relevant data that contributes to
the knowledge base associated with some of the potential factors that may be
causative to the resurgence and persistence of pertussis. This enhanced
knowledge of the potential relationship between the addition of adolescent
boosters and the requirement or recommendation of the immunization schedule
on pertussis incidence could assist in controlling the pertussis resurgence, reduce
immune waning through the use of adolescent boosters, enhance immunization
schedule timing, and lower the incidence of pertussis resulting in positive social
change through improved immunization programs and disease control strategies.
Conclusion
Pertussis is a vaccine-preventable disease, but the incidence of the disease
continues to rebound in countries with high vaccination rates (Esposito &
Principi, 2016). The use of vaccines is an essential tool to protect public health
against pertussis. Not only do vaccines protect the immunized individual, but
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they also create a state of herd immunity that protects the population (Sabbe &
Vandermeulen, 2016). Pertussis vaccines have played a protective role in
reducing the incidence of pertussis. However, with the implementation of
acellular vaccines, immunity is waning at a more rapid rate than with whole-cell
vaccines (Sabbe & Vandermeulen, 2016).
The focus of this doctoral study was to gain an understanding of the
potential relationship between the pertussis vaccination schedule, whether
recommended, required, with an adolescent booster or without an adolescent
booster, and the European country’s pertussis incidence and epidemiologic
cycles. The study findings suggest that the pertussis immunization, whether
recommended or required, does have an influence on the incidence rate of
pertussis within the populations of European countries analyzed as part of this
doctoral study. The same influence on pertussis incidence was demonstrated
related to recommended or required adolescent boosters as part of the pertussis
immunization schedule.
The doctoral study data also revealed that the pertussis immunization,
recommended or required, does not have a significant relationship with the
epidemiologic cycle of pertussis within the populations of European countries
analyzed as part of the doctoral study. The same lack of relationship on the
epidemiologic cycle of pertussis was demonstrated related to recommended or
required adolescent boosters as part of the pertussis immunization schedule.
This doctoral study assisted in providing relevant data that contributes to
the understanding of the association with some of the potential factors that may
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be contributing to the resurgence and persistence of pertussis. Additionally, the
data generated from this doctoral study provides an enhanced understanding of
the relationship between the design and requirement of the immunization
schedule on pertussis incidence. This enhanced understanding of the potential
relationship between the design and requirement of the immunization schedule
on pertussis incidence could assist in controlling the pertussis resurgence, reduce
immune waning through the use of adolescent boosters, enhance immunization
schedule timing, and lower the incidence of pertussis resulting in positive social
change through improved immunization strategy.

70

References
Althouse, B., & Scarpino, S. (2015). Asymptomatic transmission and the
resurgence of Bordetella pertussis. BMC Medicine, 12(146), 1-12.
doi:10.1186/s12916-015-0382-8
Bouchez, V., & Guiso, N. (2015). Bordetella pertussis, B. parapertussis, vaccines
and cycles of whooping cough. FEMS Pathogens and Disease, 73(7), 1-6.
doi:10.1093/femspd/ftv055
Burton, A., Monasch, R., Lautenbach, B., Gacic-Dobo, M., Neill, M., Karimov, R.,
… Birmingham, M. (2009). WHO and UNICEF estimates of national infant
immunization coverage: Methods and process. Bulletin World Health
Organization, 87(7), 535-541. doi:10.2471/BLT.08.053819
Calvert, A., & Heath, P. (2017). Pertussis. Medicine, 45(12), 735-738.
doi:10.1016/ j.mpmed.2017.09.015
Carbonetti, N. (2016). Bordetella pertussis: New concepts in pathogenesis and
treatment. Current Opinion in Infectious Diseases, 29(3), 287-294.
doi:10.1097/QCO.000000000 0000264
Casanave, C., & Li, Y. (2015). Novices’ struggles with conceptual and theoretical
framing in writing dissertations and papers for publication.
Multidisciplinary Digital Publishing Institute, 3(2), 104-119.
doi:10.3390/publications3020104
Centers for Disease Control and Prevention. (2017). Pertussis outbreak trends.
Retrieved from https://www.cdc.gov/pertussis/outbreaks/trends.html

71

Chen, Z., & He, Q. (2017). Immune persistence after pertussis vaccination.
Human Vaccines & Immunotherapeutics, 13(4), 744-756.
doi:10.1080/21645515.2016.1259780
Choi, Y., Campbell, H., Amirthalingam, G., Jan van Hoek, A., & Miller, E. (2016).
Investigating the pertussis resurgence in England and Wales, and options
for future control. BMC Medicine, 14(121), 1-11. doi:10.1186/s12916016-0665-8
Clark, T. (2014). Changing pertussis epidemiology: Everything old is new again.
The Journal of Infectious Diseases, 209(7), 978-981.
doi:10.1093/infidis/jiu001
Della Torre, J., Benevides, G., Pereira de Melo, A., & Ferreira, C. (2015).
Pertussis: The resurgence of a public health threat. Autopsy Case Reports,
5(2), 9-16. doi:10.4322/acr.2015.006
Domenech de Celles, M., Magpantay, F., King, A., & Rohani, P. (2016). The
pertussis enigma: Reconciling epidemiology, immunology, and evolution.
Proceedings of the Royal Society B: Biological Sciences, 283, (1822).
doi:10.1098/rspb.2015.2309
Domenech de Celles, M., Riolo, M., Magpantay, F., Rohani, P, & King, A. (2014).
Epidemiological evidence for herd immunity induced by acellular pertussis
vaccines. PNAS, 111(7), 716-717. doi:10.1073/pnas.1323795111
Esposito, S., & Principi, N. (2016). Immunization against pertussis in adolescents
and adults. Clinical Microbiology and Infection, 22(2016), 89-95.
doi:10.1016/j.cmi.2016.01.003

72

European Center for Disease Prevention and Control. (2018). Vaccine scheduler.
Retrieved from https://vaccine-schedule.ecdc.europa.eu/
Gambhir, M., Clark, T., Cauchemez, S., Tartof, S., Swerdlow, D., & Ferguson, N.
(2015). A change in vaccine efficacy and duration of protection explains
recent rises in pertussis incidence in the United States. PLoS
Computational Biology, 11(4), 1-16. doi:10.1371/journal.pcbi.1004138
Guiso, N., Levy, C., Romain, O., Guillot, S., Werner, A., Rondeau, M., … Cohen, R.
(2017). Whooping cough surveillance in France in pediatric private
practice in 2006-2015. Vaccine, 35(2017), 6083-6088.
doi:10.1016/j.vaccine.2017.09.072
Guiso, N. (2014). Bordetella pertussis: Why is it still circulating. Journal of
Infection, 68(1), 119-124. doi:10.1016/j.jinf.2013.09.022
Haverkate, M., D’Ancona, F., Giambi, C., Johansen, K., Lopalco, P., Cozza, V., &
Applegren, E. (2012). Mandatory and recommended vaccination in the
EU, Iceland, and Norway: results of the VENICE 2010 survey on the ways
of implementing national vaccination programs. Retrieved from
https://www.eurosurveillance.org/images/dynamic/EE
/V17N22/art20183.pdf
Heininger, U., Andre, P., Chilbek, R., Kristufkova, Z., Kutsar, K., Mangarov, A., …
Zavadska, D. (2016). Comparative epidemiologic characteristics of
Pertussis in 10 central and eastern European countries, 2000-2013. PLoS
ONE 11(16). doi:10.1371/journal.pone.0155949

73

Holland, M., & Chase, Zachary. (2014). Herd immunity and compulsory
childhood vaccination: Does the theory justify the law. Oregon Law
Review, 93(1), 1-48. Retrieved from http://hdl.handle.net/1794/18592
Kilgore, P., Salin, A., Zervos, M., & Schmitt, H. (2016). Pertussis: Microbiology,
disease, treatment, and prevention. Clinical Microbiology Reviews, 29(3),
449-486. doi:10.1128/CMR.00083-15
Kim, D., Bridges, C., & Harriman, K. (2015). Advisory committee on
immunization practices recommended immunization schedules for adults
aged 19 years or older: United States, 2015. Annals of Internal medicine,
163(3). doi:10.7326/M14-2755
Lapidot, R., & Gill, C. (2016). The pertussis resurgence: Putting together the
pieces of the puzzle. Tropical Diseases, Travel Medicine, and Vaccines,
2(26), 1-10. doi:10.1186/s40794-016-0043-8
Locht, C. (2016). Pertussis: Acellular, whole cell, new vaccines, what to choose.
Expert Review of Vaccines, 15(6), 671-673.
doi:10.1586/14760584.2016.1161511
Locht, C. (2016). Pertussis Where did we go wrong and what can we do about it.
Journal of Infection, 72(2016), 34-40. doi:10.1016/j.jinf.2016.04.020
Muloiwa, R., Kagina, B., Engel, M., & Hussy, G. (2015). The burden of pertussis
in low- and middle-income countries since the inception of the Expanded
Program on Immunization (EPI) in 1974: A systematic review protocol.
BioMed Central, 4(62), 1-7. doi:10.1186/s13643-015-0053-z

74

Nitsch-Osuch, A., Korzeniewski, K., Kucher, E., Zielonka, T., Zycinska, K., &
Wardyn, K. (2013). Epidemiological and immunological reasons for
pertussis vaccination in adolescents and adults. Respiratory Physiology, &
Neurobiology, 187(1), 99-103. doi:10.1016/j.resp.2013.02.007
Plans-Rubio, P. (2014). Is current prevention strategy based on vaccination
coverage and epidemiological surveillance sufficient to achieve measles
and rubella elimination in Europe. Expert Review of Anti-Infective
Therapy, 12(7), 723-726. doi:10.1586/ 14787210.2014.917047
Radke, S., Petousis-Harris, H., Watson, D., Gentles, D., & Turner, N. (2016). Agespecific effectiveness following each dose of acellular pertussis vaccine in
infants and children in New Zealand. Vaccine, 35(1), 177-183.
doi:10.1016/j.vaccine.2016.11.00 4
Riolo, M., & Rohani, P. (2015). Combating pertussis resurgence: One booster
vaccination schedule does not fit all. Proceedings of the National
Academy of Sciences, 112(5), 1-6. doi:10.1073/pnas.1415573112
Saadatian-Elahi, M., Plotkin, S., Mills, K., Halperin, S., McIntyre, P., Picot, V., …
Johnson, D. (2016). Pertussis: Biology, epidemiology, and prevention.
Vaccine, 34(48), 5819-5826. doi:10.1016/j.vaccine.2016.10.029
Sabbe, M. & Vandermeulen, C. (2016). The resurgence of mumps and pertussis.
Human Vaccines & Immunotherapeutics, 12(4), 955-959.
doi:10.1080/21645515.2015.1113357

75

Sealy, K., Belcher, T., & Preston, A. (2016). Bordetella pertussis epidemiology
and evolution in the light of pertussis resurgence. Infection, Genetics and
Evolution, 40(2016), 136-143. doi:10.1016/j.meegid.2016.02.032
Smith, A., Ayanian, J., Covinsky, K., Landon, B., McCarthy, E., Wee, C., &
Steinman. (2011). Conducting high-value secondary dataset analysis: An
introductory guide and resources. Journal of General Internal Medicine,
26(8), 920-929. doi:10.1007/s11606-010-1621-5
Tan, T., Dalby, T., Forsyth, K., Halperin, S., Heininger, U., Hozbor, D., … Konig,
C. (2015). Pertussis across the globe recent epidemiologic trends from
2000 to 2013. The Pediatric Infectious Disease Journal, 34(9).
doi:10.1097/INF.0000000000000795
Terranella, A., Rea, V., Griffith, M., Manning, S., Sears, S., Farmer, A., … Patel,
M. (2016). Vaccine effectiveness of tetanus toxoid, reduced diphtheria
toxoid, and acellular pertussis vaccine during a pertussis outbreak in
Maine. Vaccine, 34(22), 2496-2500. doi:10.1016/j.vaccine.2016.03.083
U.S. Health and Human Services. (2018). Glossary. Retrieved from
https://www.vaccines.gov/ resources/glossary/index.html
Walden University. (2014). Doctoral study premise: Doctor of public health.
Retrieved from
https://drive.google.com/a/waldenu.edu/file/d/0B4XiaHN6ICGINWpTV
k5mOUFSOW8/view?pref=2&pli=1
World Health Organization. (2018). WHO vaccine-preventable disease:
monitoring system 2018 global summary. Retrieved from

76

http://apps.who.int/immunization_monitoring/global
summary/countries?countrycriteria%5Bcountry%5D%5B%5D=USA
World Health Organization. (2016). Pertussis vaccines: WHO position paper,
August 2015- Recommendations. Vaccine, 34(12), 1423-1425.
doi:10.1016/j.vaccine.2015.10.136
World Health Organization. (2011). WHO vaccine-preventable disease:
monitoring system 2010 global summary. Retrieved from
http://www.who.int/immunization/documents/ monitoring/en/

